jcp conference-coverage

Conference Coverage

Conference Coverage

AI in Cancer Care: Separating Fact from Fiction

10/06/2023

James Hamrick, MD, discusses his presentation "AI in Cancer Care: Separating Fact from Fiction" at the 2023 Clinical Pathways Congress + Cancer Care Business Exchange meeting.

James Hamrick, MD, discusses his...

10/06/2023

Journal of Clinical Pathways

Conference Coverage

CPC & CBEx Session Preview: Updates from Washington, Healthcare Industry Consolidation, and Cancer Care at Home

10/03/2023

Barbara McAneny , MD;

CPC & CBEx faculty member Barbara McAneny, MD, gives a preview of her three featured sessions from the conference, including key points on health care industry consolidation, legislative updates, and important considerations for delivering...

CPC & CBEx faculty member...

10/03/2023

Journal of Clinical Pathways

Conference Coverage

Use of Pharmacogenomic Testing to Predict Bruton’s Tyrosine Kinase Inhibitor Treatment Intolerance

08/09/2023

Emry Lloyd ;

Researchers conducted a study to determine whether cytochrome P450 polymorphisms can contribute to treatment intolerance in patients receiving Bruton’s tyrosine kinase inhibitors.

Researchers conducted a study to...

08/09/2023

Journal of Clinical Pathways

Videos

Study Examines the Association Between Oncologists’ Receipt of Pharmaceutical Industry Payments and Use of Nonrecommended/Low-Value Treatments

07/20/2023

Aaron P. Mitchell , MD;

Aaron P. Mitchell, MD, MPH, discusses his research on the association of pharmaceutical industry payments to oncologists and their increased use of nonrecommended and/or low-value treatment methods.

Aaron P. Mitchell, MD, MPH,...

07/20/2023

Journal of Clinical Pathways

Conference Coverage

Study Evaluates Sociodemographic Factors and Survival Outcomes for Patients with CLL/SLL

07/18/2023

Emry Lloyd ;

Researchers analyzed whether sociodemographic characteristics influence the overall survival rate of Hispanic vs non-Hispanic patients with CLL/SLL

Researchers analyzed whether...

07/18/2023

Journal of Clinical Pathways

Conference Coverage

Study Compares the Efficacy and Safety of Acalabrutinib vs Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia

07/07/2023

Emry Lloyd ;

Researchers conducted a study to compare two drugs for R/R CLL treatment safety: acalabrutinib and zanubrutinib.

Researchers conducted a study to...

07/07/2023

Journal of Clinical Pathways

Conference Coverage

Overall Survival Analysis of Patients with R/R LBCL Receiving Axicabtagene Ciloleucel vs Standard of Care Therapy: ZUMA-7 Study

06/27/2023

Grace Taylor , MS, MA;

Jason Westin, MD, and colleagues examined the overall survival of patients with R/R LBCL who received axicabtagene ciloleucel vs standard of care for second-line therapy as part of the ZUMA-7 clinical trial.

Jason Westin, MD, and colleagues...

06/27/2023

Journal of Clinical Pathways

Conference Coverage

Evaluation of a Medication Acquisition Program for Patient Access to Off-Label Treatment

06/21/2023

Emry Lloyd ;

Researchers analyzed the success of their institution’s medication acquisition program for patients with cancer, including tracking clinical benefit.

Researchers analyzed the success...

06/21/2023

Journal of Clinical Pathways

Videos

The Impact of Social Determinants of Health on Use of Germline Genetic Testing for Triple-Negative Breast Cancer

06/20/2023

Barb Kunz ;

Barb Kunz, the US Oncology Network, discusses her study on the impact of social determinants of health on use of germline genetic testing for triple-negative breast cancer in the community oncology setting.

Barb Kunz, the US Oncology...

06/20/2023

Journal of Clinical Pathways

Conference Coverage

Study Examines Real-World Outcomes of Novel Treatments for Diffuse Large B-Cell Lymphoma

06/14/2023

Emry Lloyd ;

Researchers conducted a retrospective analysis to evaluate the outcomes of patients with R/R DLBCL treated with novel therapies, with a subanalysis of patients who received CAR T prior to novel therapies.

Researchers conducted a...

06/14/2023

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Update: Impact on NSCLC Landscape

11/15/2024

The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.

The updated 2024 NCCN...

11/15/2024

Journal of Clinical Pathways

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products